Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology from UK-based LumiraDx. The transaction, valued at $295 million, is anticipated to conclude in mid-2024, with an additional payment of up to $55 million to cover LumiraDx’s point-of-care business expenses until the deal’s closure.
The technology in question is a multifaceted platform capable of conducting a broad spectrum of immunoassay and clinical chemistry tests. These tests are notable for their stability at room temperature and their applicability across various disease areas, enhancing Roche’s diagnostic capabilities.- Flcube.com
